Cerestat antagonist: Began an international Phase II dose-response trial

Cambridge NeuroScience Inc. (CNSI), Cambridge, Mass. Product: Cerestat antagonist of NMDA receptors Indication: Stroke Status: Began an international Phase II dose-response trial in 120 patients to c...